Related references
Note: Only part of the references are listed.Therapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor
Sang Min Lim et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
Michael C. Burns et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Benchmarking in Vitro Covalent Binding Burden As a Tool To Assess Potential Toxicity Caused by Nonspecific Covalent Binding of Covalent Drugs
Upendra P. Dahal et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2013)
ConSurf: Using Evolutionary Data to Raise Testable Hypotheses about Protein Function
Gershon Celniker et al.
ISRAEL JOURNAL OF CHEMISTRY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Structural and Biophysical Characterization of the Syk Activation Switch
Ulrich Graedler et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling
Gunther Zimmermann et al.
NATURE (2013)
ERK Pathway Inhibitors: How Low Should We Go?
Moriah H. Nissan et al.
CANCER DISCOVERY (2013)
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation
Qi Sun et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Ras inhibition via direct Ras binding-is there a path forward?
Weiru Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Vincent A. Miller et al.
LANCET ONCOLOGY (2012)
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
Till Maurer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
Heidi Greulich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The diverse roles of Rac signaling in tumorigenesis
Natalie A. Mack et al.
CELL CYCLE (2011)
In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Matthew P. Patricelli et al.
CHEMISTRY & BIOLOGY (2011)
Role of Rho GTPases and their regulators in cancer progression
Rajamani Rathinam et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Non-ATP Competitive Protein Kinase Inhibitors
L. Garuti et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy?
Patrick J. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids
Haim Ashkenazy et al.
NUCLEIC ACIDS RESEARCH (2010)
A new bioinformatics analysis tools framework at EMBL-EBI
Mickael Goujon et al.
NUCLEIC ACIDS RESEARCH (2010)
Targeting the cancer kinome through polypharmacology
Zachary A. Knight et al.
NATURE REVIEWS CANCER (2010)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase
Julie A. Spicer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Functional interrogation of the kinome using nucleotide acyl phosphates
Matthew P. Patricelli et al.
BIOCHEMISTRY (2007)
Rho GTPases: Promising cellular targets for novel anticancer drugs
G Fritz et al.
CURRENT CANCER DRUG TARGETS (2006)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures
M Landau et al.
NUCLEIC ACIDS RESEARCH (2005)
The Ras superfamily at a glance
K Wennerberg et al.
JOURNAL OF CELL SCIENCE (2005)
Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas
S Jones et al.
BRITISH JOURNAL OF CANCER (2004)
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf
MO Bergo et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
J Rinehart et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of the farnesyl transferase inhibitor r115777 in patients with advanced non-small-cell lung cancer
AA Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
ConSurf: Identification of Functional Regions in Proteins by Surface-Mapping of Phylogenetic Information
F Glaser et al.
BIOINFORMATICS (2003)
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ
ME Pacold et al.
CELL (2000)
Share Paper
